ABEC Expands Process Sciences Support for Biomanufacturing

Why It Matters

The expanded capability gives biomanufacturers a data‑driven partner that can shorten time‑to‑market and lower R&D expenses in an increasingly competitive industry.

Key Takeaways

• ABEC adds dedicated Process Sciences group for end‑to‑end bioprocess support.
• Team blends experimental testing with CFD to accelerate scale‑up decisions.
• Facilities run mixing studies from 200 mL up to 6,000 L.
• Expertise covers microbial fermentation and animal cell culture processes.
• Custom equipment designed around process needs, not standard hardware.

Pulse Analysis

Biopharma manufacturers face mounting pressure to bring therapies to market faster while maintaining stringent quality standards. Traditional process development often relies on trial‑and‑error experiments that can extend timelines and inflate costs. ABEC’s expanded Process Sciences group addresses this gap by offering a holistic suite of services that merge hands‑on experimentation with high‑fidelity computational modeling. By applying computational fluid dynamics, the firm can predict mixing behavior, mass transfer, and shear forces before physical trials, enabling more informed design choices early in the development cycle.

The technical backbone of ABEC’s offering lies in its ability to conduct mixing studies at scales ranging from 200 mL bench‑scale vessels to 6,000 L pilot reactors. These real‑world runs, coupled with live cell or microbial cultures, generate rich datasets that feed into Quality by Design (QbD) frameworks. Engineers scrutinize critical parameters such as agitation speed, CO₂ stripping efficiency, and blend time to fine‑tune processes for both microbial fermentation and animal cell culture platforms. This depth of insight reduces the number of iterative experiments required, shortens scale‑up timelines, and mitigates risks associated with technology transfer to commercial facilities.

For the industry, ABEC’s integrated approach translates into tangible business benefits. Faster development cycles mean earlier market entry, which is crucial for high‑value biologics and emerging therapies. The ability to design custom equipment around specific process requirements, rather than adapting to generic hardware, further enhances operational efficiency and product consistency. As biomanufacturing continues to evolve toward more personalized and complex modalities, partners that can deliver data‑driven, end‑to‑end solutions like ABEC are poised to become strategic assets for pharmaceutical companies seeking competitive advantage.